Toby Gamlen

Prior to joining the Gene Medicine group in October 2017 I undertook my doctoral studies in the Molecular Virology group at the University of Leeds investigating the induction of apoptosis by flavivirus proteins. Subsequently, I have under taken post-doctoral research into the sub-cellular localization of the SARS N protein, the involvement of Helicobacter pylori infection in the development of iron deficiency and the role excess glucose in the bloodstream plays in impairing thrombolysis in patients with diabetes. 

In addition to my role managing the Gene Medicine laboratory my research work in Oxford is focussed on the production, quantification and characterisation of novel lentiviral vectors for the treatment of genetic disease. Our group is currently preparing for a first-in-human clinical trial of a lentiviral treatment for cystic fibrosis and developing our technology platform to investigate treatment options for additional lung diseases and the secretion of protective antibodies from lentiviral vectors for novel immunisation approaches.